Volume 2
Number 1, January 2020Efficacy and Safety of Voriconazole in the treatment of resistant cases of Dermatophytosis
DOI: https://doi.org/10.47648/zhswmcj.2020.v0201.01
Md. Abdulla-Hel Kafi1 , Mohsena Akter2 , Rumana Khan3 , Syed Shair Ahmed4 , Md. Jonayed Hassan5 , Mohammad Shariful Hassan6
Abstract
This is a descriptive type of longitudinal study conducted among Hundred clinically diagnosed cases of dermatophytes attending at skin out patients department of Zainul Haque Sikder Women’s Medical College, Bangladesh from August 2018 to August 2019 to observe the efficacy and safety of voriconazole among the resistant cases of dermatophytosis. Among 100 patients, 40 were males and 60 females between ages 20 and 65 years of all age group with clinical, mycological diagnosis of dermatophytosis. To find out antifungal resistance pattern as well as efficacy and Safety of Voriconazole among dermatophytes. (Skin, hair and nail samples were taken aseptically. All patients were resistant against present treatment options like: fluconazole, itraconazole & terbinafine etc.) All patients were treated with Voriconazole. Duration of treatment of each patient was 4 weeks. Resistance against fluconazole and terbinafine was most common, 85.33% and 58% respectively. 5% resistance against voriconazole was observed in this study. Resistance against fluconazole was noted among all species of dermatophytes, followed by terbinafine. Among 100 patients 80% was fully cure and rest of 15 % were partially cure with 5% resistant of Voriconazole which is seems to be more effective and safer against dermatophytosis.
Keywords: Resistant Dermatophytes, Antifungal, Efficacy, Safety, Voriconazole.
- Professor, Department of Dermatology
- Assistant Professor, Department of Dermatology
- Medical Officer, Department of Dermatology
- Medical Officer, Department of Dermatology
- Department of Pharmaceutical Science
- Department of Pharmacy
